TERN241220C1000
- 0.00
- 0.000.00%
Terns Pharmaceuticals Newsroom
Oppenheimer Maintains Terns Pharmaceuticals(TERN.US) With Buy Rating, Maintains Target Price $20
H.C. Wainwright Maintains Terns Pharmaceuticals(TERN.US) With Hold Rating, Maintains Target Price $7.5
Hold Rating on Terns Pharmaceuticals' TERN-701 Due to Uncertain Efficacy Despite Promising Safety Profile
JMP Securities Maintains Terns Pharmaceuticals(TERN.US) With Buy Rating, Maintains Target Price $20
HC Wainwright & Co. Reiterates Neutral on Terns Pharma, Maintains $7.5 Price Target
Terns Pharmaceuticals Is Maintained at Outperform by Oppenheimer
Terns Pharmaceuticals Price Target Raised to $20.00/Share From $17.00 by Oppenheimer
Terns Pharma Analyst Ratings
JMP Securities Maintains Terns Pharmaceuticals(TERN.US) With Buy Rating, Maintains Target Price $20
TD Cowen Maintains Terns Pharmaceuticals(TERN.US) With Buy Rating
TD Cowen Maintains Terns Pharmaceuticals(TERN.US) With Buy Rating
Terns Pharma Analyst Ratings
BMO Capital Maintains Terns Pharmaceuticals(TERN.US) With Buy Rating, Maintains Target Price $26
H.C. Wainwright Maintains Terns Pharmaceuticals(TERN.US) With Hold Rating, Raises Target Price to $7.5
JMP Securities Maintains Terns Pharmaceuticals(TERN.US) With Buy Rating, Maintains Target Price $20
Terns Pharmaceuticals: Promising Oncology Developments and Strategic Pipeline Diversification Justify Buy Rating
Mizuho Securities Maintains Terns Pharmaceuticals(TERN.US) With Buy Rating
Terns Pharmaceuticals Initiated at Outperform by Oppenheimer
Oppenheimer Initiates Terns Pharmaceuticals(TERN.US) With Buy Rating, Announces Target Price $17
Mizuho Securities Maintains Terns Pharmaceuticals(TERN.US) With Buy Rating, Raises Target Price to $14